Our data demonstrate that the combined treatment of BRAF mutated thyroid cancer cells with the BRAFV600E-inhibitor PLX4720 and the SRC-inhibitor dasatinib results in a synergistic increase in the anti-proliferative and apoptotic responses in vitro. The gene discussed is SRC; the disease is thyroid cancer.